

Dystrophin - Pipeline Review, H1 2020

<https://marketpublishers.com/r/DBEF9AE823A2EN.html>

Date: February 2020

Pages: 122

Price: US\$ 3,500.00 (Single User License)

ID: DBEF9AE823A2EN

Abstracts

Dystrophin - Pipeline Review, H1 2020

SUMMARY

Dystrophin (DMD) pipeline Target constitutes close to 49 molecules. Out of which approximately 43 molecules are developed by companies and remaining by the universities/institutes. The latest report Dystrophin (DMD) - Pipeline Review, H1 2020, outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5, 1, 24 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy and Muscular Dystrophy.

Furthermore, this report also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party

sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)

The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects

The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create

effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Dystrophin (DMD) - Overview

Dystrophin (DMD) - Therapeutics Development

Dystrophin (DMD) - Therapeutics Assessment

Dystrophin (DMD) - Companies Involved in Therapeutics Development

Dystrophin (DMD) - Drug Profiles

Dystrophin (DMD) - Dormant Products

Dystrophin (DMD) - Discontinued Products

Dystrophin (DMD) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Alpha Anomeric, H1 2020
Pipeline by Audentes Therapeutics Inc, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by Dystrogen Therapeutics SA, H1 2020
Pipeline by Editas Medicine Inc, H1 2020
Pipeline by Evox Therapeutics Ltd, H1 2020
Pipeline by FibroGenesis LLC, H1 2020
Pipeline by MyoGene Bio LLC, H1 2020
Pipeline by Nippon Shinyaku Co Ltd, H1 2020
Pipeline by NS Pharma Inc, H1 2020
Pipeline by OliPass Corporation, H1 2020
Pipeline by Pepgen Ltd, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Sarepta Therapeutics Inc, H1 2020
Pipeline by Sutura Therapeutics Ltd, H1 2020
Pipeline by Tolerion Inc, H1 2020
Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Alpha Anomeric

Audentes Therapeutics Inc

Daiichi Sankyo Co Ltd

Dystrogen Therapeutics SA

Editas Medicine Inc

Evox Therapeutics Ltd

FibroGenesis LLC

MyoGene Bio LLC

Nippon Shinyaku Co Ltd

NS Pharma Inc

OliPass Corporation

Pepgen Ltd

Pfizer Inc

Sarepta Therapeutics Inc

Sutura Therapeutics Ltd

Tolerion Inc

Vertex Pharmaceuticals Inc

I would like to order

Product name: Dystrophin - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/DBEF9AE823A2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DBEF9AE823A2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970